Cincinnati Children's Hospital Medical Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1883-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
632
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (472 trials with phase data)• Click on a phase to view related trials
Neurodevelopmental Outcomes in Cerebral Visual Impairment
- Conditions
- Cerebral Visual Impairment
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 600
- Registration Number
- NCT07212010
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Evaluation of the SMART IBD App in Pediatric IBD
- Conditions
- Inflammatory Bowel Disease (IBD)IBD (Inflammatory Bowel Disease)IBD - Inflammatory Bowel DiseaseIndeterminate ColitisUlcerative Colitis (UC)Crohn Disease (CD)
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 70
- Registration Number
- NCT07195123
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Thebaine Urine Testing
- Conditions
- Urine Specimen Collection
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT07192887
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Safety and Efficacy of FETO in CDH Phase III
- Conditions
- Congenital Diaphragmatic HerniaPulmonary HypoplasiaPulmonary Hypertension
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 75
- Registration Number
- NCT07187206
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio, United States
Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
- Conditions
- Sickle Cell Anemia (HbSS)Sickle-β0-thalassemia (HbSβ0)
- Interventions
- Drug: PK-optimized oral hydroxyurea at MTD until 15 years of age.
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 50
- Registration Number
- NCT07177300
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 127
- Next
News
Blue Lake and CyanVac Report Promising Phase 1 Results for Intranasal COVID-19 Vaccine CVXGA
Blue Lake Biotechnology and CyanVac published full Phase 1 data in Science Advances showing their intranasal COVID-19 vaccine candidate CVXGA demonstrated safety and immunogenicity in 72 healthy subjects aged 12-51 years.
First US Nasal COVID-19 Vaccine Shows 67% Infection Reduction in Phase 1 Trial
CyanVac's CVXGA nasal COVID-19 vaccine demonstrated a 67% reduction in infection risk compared to unvaccinated individuals in the first US-based phase 1 clinical trial.
FDA Approves Gamifant as First Treatment for Macrophage Activation Syndrome in Still's Disease
The FDA has approved Gamifant (emapalumab-lzsg) as the first-ever treatment for adults and children with macrophage activation syndrome in Still's disease, marking a significant breakthrough for patients with this life-threatening condition.
NIH Launches Influenza Human Challenge Study to Advance Vaccine Development
The National Institute of Allergy and Infectious Diseases (NIAID) has initiated a clinical trial where healthy adults will be deliberately infected with influenza virus under controlled conditions at four research sites across the US.
FDA Approves First Treatment for Primary Hemophagocytic Lymphohistiocytosis, Marking 24-Year Breakthrough
The FDA has approved emapalumab-lzsg (Gamifant) as the first treatment specifically indicated for primary hemophagocytic lymphohistiocytosis (HLH), an ultra-rare and life-threatening immune disorder.